Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pulse Biosciences (PLSE) Invested Capital (2020 - 2025)

Pulse Biosciences has reported Invested Capital over the past 6 years, most recently at $92.7 million for Q3 2025.

  • Quarterly results put Invested Capital at $92.7 million for Q3 2025, up 17.14% from a year ago — trailing twelve months through Sep 2025 was $92.7 million (up 17.14% YoY), and the annual figure for FY2024 was $114.9 million, up 158.93%.
  • Invested Capital for Q3 2025 was $92.7 million at Pulse Biosciences, down from $104.5 million in the prior quarter.
  • Over the last five years, Invested Capital for PLSE hit a ceiling of $118.5 million in Q1 2025 and a floor of -$10.7 million in Q1 2023.
  • Median Invested Capital over the past 5 years was $44.4 million (2021), compared with a mean of $49.4 million.
  • Peak annual rise in Invested Capital hit 2073.31% in 2023, while the deepest fall reached 151.29% in 2023.
  • Pulse Biosciences' Invested Capital stood at $44.4 million in 2021, then plummeted by 105.07% to -$2.2 million in 2022, then skyrocketed by 2073.31% to $44.4 million in 2023, then skyrocketed by 158.93% to $114.9 million in 2024, then decreased by 19.3% to $92.7 million in 2025.
  • The last three reported values for Invested Capital were $92.7 million (Q3 2025), $104.5 million (Q2 2025), and $118.5 million (Q1 2025) per Business Quant data.